Myeloproliferative disorders-oreb (2)

Nankunda Oreb

The material introduces myeloproliferative disorders (MPNs) as clonal hematopoietic stem‑cell diseases, highlighting essential thrombocythemia, polycythemia vera, primary myelofibrosis, and chronic myeloid leukemia. It reviews WHO 2016 diagnostic criteria, key molecular mutations such as JAK2, CALR, and MPL, and the clinical manifestations including splenomegaly, thrombosis, and progression risk. Detailed risk‑stratification models for polycythemia vera and myelofibrosis are presented, followed by therapeutic considerations and treatment algorithms. The presentation also touches on secondary causes and epidemiologic aspects of MPNs.